RAD-140 vs LGD-4033: Best SARM Comparison

All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice.

If you’re comparing RAD-140 vs LGD-4033, you’re looking at the two heavyweights of SARM research. Both are among the most-studied selective androgen receptor modulators. Both deliver strong anabolic data. But they’re not the same compound — and the differences matter when you’re designing results-focused studies.

This RAD 140 vs LGD 4033 comparison breaks down the mechanism, research data, selectivity, side effect profiles, and practical research considerations so you can make an informed decision for your lab work.

Mechanism of Action: How Each Compound Works

RAD-140 (Testolone)

RAD-140 is a nonsteroidal SARM that binds androgen receptors with high affinity and high selectivity for muscle and bone tissue. Key mechanism highlights:

High AR binding affinity — competitive with testosterone and DHT in muscle tissue models
Tissue selectivity — demonstrates strong anabolic activity in skeletal muscle with minimal agonist activity in prostate tissue in preclinical models
Neuroprotective properties — emerging research suggests RAD-140 may have neuroprotective effects via androgen receptor signaling in brain tissue, a unique property among SARMs
No aromatization — RAD-140 does not convert to estrogen, eliminating one class of side effects seen with traditional androgens

LGD-4033 (Ligandrol)

LGD-4033 is also a nonsteroidal SARM but with a slightly different receptor interaction profile:

Direct AR agonism with potent anabolic signaling in muscle tissue
High oral bioavailability in preclinical models — one of the most orally bioavailable SARMs studied
Strong lean mass signal — LGD-4033 research consistently shows robust effects on lean body mass markers
Minimal off-target activity at therapeutic doses in animal models

Both compounds are selective. Both are potent. The key difference: RAD-140 tends to produce stronger anabolic signaling per unit of receptor engagement, while LGD-4033 delivers highly consistent lean mass research outcomes with a slightly more favorable tolerability profile in animal studies.

Head-to-Head: Research Data Comparison

Here’s where the rubber meets the road. This SARM comparison guide wouldn’t be complete without a direct data breakdown:

Anabolic potency (preclinical): RAD-140 shows higher anabolic:androgenic ratio in animal models — approximately 90:1 versus LGD-4033’s roughly 10:1. Both are highly anabolic relative to testosterone, but RAD-140’s ratio is more aggressive.
Lean mass research data: LGD-4033 has more published data specifically on lean mass outcomes. The Phase 1 clinical trial data for LGD-4033 is among the most robust in the SARMs category.
Muscle selectivity: Both demonstrate strong muscle tissue selectivity. RAD-140 shows slightly more prostate-sparing data in preclinical models.
Bone density: Both show positive effects on bone mineral density markers in animal studies. LGD-4033 has been specifically studied for osteoporosis-related endpoints.

RAD-140 vs LGD-4033 Quick Comparison

Compound class: Both nonsteroidal SARMs
AR binding affinity: RAD-140 > LGD-4033
Anabolic:androgenic ratio: RAD-140 ~90:1 vs LGD-4033 ~10:1
Oral bioavailability: Both high; LGD-4033 slightly better documented
Lean mass signal strength: Both strong; LGD-4033 more clinical data
Prostate tissue impact: Both minimal; RAD-140 slightly more selective
Estrogenic activity: Neither compound aromatizes
Half-life (animal models): RAD-140 ~12-18h; LGD-4033 ~24-36h
Available clinical data: LGD-4033 has more published Phase 1 data; RAD-140 has Phase 1 data with limited publication
Primary research use: RAD-140 → anabolic power studies; LGD-4033 → lean mass & BMD studies

Best SARM for Muscle: Which Wins?

The question “best SARM for muscle” depends on what you’re researching.

Choose RAD-140 if your research priorities are:

Maximum anabolic signaling per receptor engagement
Neuroprotection pathway exploration
Shorter half-life for flexible protocol design
Aggressive results-focused studies

Choose LGD-4033 if your research priorities are:

Consistent lean mass research data with clinical backing
Longer half-life for less frequent dosing in applicable models
Bone mineral density research endpoints
More published safety and tolerability data

For researchers who want both compounds for comparative studies, BioPharma carries RAD-140 and LGD-4033 with full COA verification.

Side Effect Profiles: What the Research Shows

Neither compound is side-effect-free. Here’s what the preclinical and limited clinical data report:

RAD-140 Side Effect Considerations

Testosterone suppression: Expected at research-relevant doses in animal models. The degree depends on dose and duration.
Lipid changes: HDL reduction and LDL increase observed in some studies — consistent with androgen receptor activation patterns.
Liver enzymes: Generally within normal limits in available data, though monitoring is prudent in longer-term studies.
Estrogen-related: No aromatization, but estrogen receptor feedback changes may occur through HPG axis suppression.

LGD-4033 Side Effect Considerations

Testosterone suppression: Dose-dependent suppression observed in Phase 1 data, generally less severe than RAD-140 at equivalent anabolic doses.
Lipid changes: Similar HDL/LDL shifts as RAD-140, potentially slightly milder.
Liver enzymes: No significant hepatotoxicity signals in published Phase 1 data.
Water retention: Some animal data suggests mild fluid retention markers — potentially relevant for researchers distinguishing lean vs. total mass outcomes.

Bottom line: LGD-4033 has the cleaner published tolerability profile, largely because it has more clinical data. RAD-140’s profile is slightly more aggressive, consistent with its higher anabolic ratio.

Research Protocol Considerations

Half-Life and Dosing Frequency

RAD-140 half-life of 12-18 hours supports once-daily dosing models in applicable species
LGD-4033 half-life of 24-36 hours supports once-daily or even less frequent dosing
Longer half-life can mean steadier blood levels but slower washout — design protocols accordingly

Solubility and Administration

Both compounds are soluble in DMSO and compatible with standard cell culture and preclinical administration methods
Both are orally bioavailable in animal models, which is why they were developed as oral SARM candidates

Research Duration

Short-term gene expression studies: 1-4 weeks in applicable models
Lean mass and BMD endpoints: 6-12+ weeks in most animal study designs
Always incorporate appropriate controls and recovery period monitoring

For comprehensive background on each compound, see our dedicated guides: RAD-140 Research Guide and LGD-4033 Research Guide.

Frequently Asked Questions

Which is stronger, RAD-140 or LGD-4033?

In terms of anabolic:androgenic ratio, RAD-140 is more potent per unit of receptor engagement. However, LGD-4033 delivers highly consistent lean mass research outcomes with more published clinical data. “Stronger” depends on your research endpoint.

Can RAD-140 and LGD-4033 be researched together?

Some researchers combine them in stacked protocols for additive anabolic signaling. However, stacking increases androgenic load and suppression risk. Each compound should be characterized individually before combination studies.

Is LGD-4033 better for beginners?

LGD-4033 has more published tolerability data and a slightly milder side effect profile in available studies, making it a common starting point for researchers new to SARM work. Its longer half-life also simplifies protocol design.

Do either of these SARMs require PCT in research models?

Both compounds cause dose-dependent testosterone suppression in applicable animal models. Researchers should plan for HPG axis recovery monitoring in study designs, particularly for longer protocols.

Which SARM is better for bone density research?

LGD-4033 has more published data on bone mineral density endpoints and was partially developed for osteoporosis-related applications. RAD-140 also shows positive BMD markers but has less dedicated bone research data.

Related Research Guides

SARMs Research Guide — Full category overview and compound directory
RAD-140 Research Guide — Deep dive into testolone data and mechanisms
LGD-4033 Research Guide — Complete ligandrol research analysis

Source Lab-Verified SARMs for Your Research

Whether your next study calls for RAD-140, LGD-4033, or both, BioPharma delivers batch-tested, COA-verified research compounds with full purity documentation.

👉 Shop RAD-140 | Shop LGD-4033